Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia
Status:
Completed
Trial end date:
2002-07-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, dose-ranging, placebo-controlled trial to determine the
lipid-lowering efficacy and safety of BMS-298585 (muraglitazar) alone in combination with
pravastatin in subjects with mixed dyslipidemia.